One step closer to a coronavirus vaccine

Posted by: The Conversation Global

Date: Wednesday, 22 July 2020


It’s been a tough six months, but it may be time for cautious optimism. Early data shows that the coronavirus vaccine being developed by the University of Oxford and AstraZeneca leads to a strong antibody response – meaning effective protection could be within reach.

Rebecca Ashfield, a scientist working on the trial, explains the encouraging news that within 28 days, the vaccine induced antibodies in all the people who received it. The vaccine also induces T cells that recognise the coronavirus – another clue that it will offer protection.

The crucial next step is to confirm that the vaccine actually stops people from getting COVID-19. All eyes will be on the next round of tests taking place in South Africa and Brazil.

Rob Reddick

Commissioning Editor, COVID-19


Oxford immunologist on coronavirus vaccine: our early results look highly promising

Rebecca Ashfield, University of Oxford

The experimental vaccine stimulates the creation of antibodies. Now we need to show that these effectively protect us from the coronavirus.

Health + Medicine

Coronavirus: B cells and T cells explained

Raj Thaker, University of Essex

It's hard to discuss COVID without referring to white blood cells. Here is a primer on the two you need to know about.

COVID-19 promotes innovative HIV service delivery in Cape Town

Jonathan Euvrard, University of Cape Town; Mary-Ann Davies, University of Cape Town

COVID-19 has stretched South Africa's public health services to capacity. In response, the services have increased their capacity through innovation.

Politics + Society

Why international players have a duty to help the search for peace in Cameroon

James Angove, University of Oxford; Roxana Willis, University of Oxford

Cameroon's anglophone crisis is not simply a dispute between two feuding groups: a range of international actors have been architects of the current situation.

Russian cyberthreat extends to coronavirus vaccine research

Dorothy Denning, Naval Postgraduate School

The Russian cyberthreat, now targeting coronavirus vaccine research, goes back over three decades, extends into the country's educational systems and criminal worlds, and shows no signs of letting up.


Danakali eyes finish line for Eritrea potash project

Dehai Events